| Ytd | -14.01% | |
| 1y | 43.26% |
| Open | 7.59 | Prev Close | 7.55 | Low | 7.37 | High | 7.60 | Mkt Cap | 30.56M |
| Vol | 4.65K | Avg Vol | 17.93K | EPS | -13.99 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 6.98 | 200-d Avg | 8.44 | 1yr Est | 0.00 |
The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) w